



XANAMEM™ CLINICAL ADVISORY BOARD DISCUSSES ALZHEIMER'S AND XANAMEM™ DEVELOPMENT, IN A BROADCAST VIA OPEN BRIEFING

- **Investor conference call with the Xanamem™ Clinical Advisory Board**
- **Shareholders spoke live to Professors Craig Ritchie, Colin Masters and Jeff Cummings, and Actinogen CEO Dr Bill Ketelbey on the potential for Xanamem™ as a promising new treatment for Alzheimer's disease**
- **Profs. Ritchie, Masters and Cummings, all global experts in Alzheimer's R&D, recently appointed to the Xanamem™ Clinical Advisory Board.**
- **Input from the Clinical Advisory Board will help design a Phase II efficacy and safety study of Xanamem™ in Alzheimer's disease. The study will run in Australia and New Zealand, the UK and the US following an Investigational New Drug (IND) application to the Food and Drug Administration's (FDA)**

Sydney, 16 April 2015: Actinogen Limited (Actinogen Medical, ASX: ACW), has today released a recording and transcript of a conference call with its Xanamem™ Clinical Advisory Board held on **Tuesday 14 April 2015 at 9.00am AEST.**

If you were unable to participate in the call, we highly recommend listening to the recording or reading the transcript – see links below.

On the call, Actinogen Medical Chief Executive Officer, Dr Bill Ketelbey and members of the Advisory Board, Professor Craig Ritchie from Edinburgh, Professor Colin Masters from Melbourne and Professor Jeff Cummings from the Cleveland Clinic in the USA, spoke about Actinogen's development of its promising lead research drug candidate, Xanamem™ and its potential in early Alzheimer's disease.

Xanamem™ works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer's disease.

The Advisory Board also answered a number of questions on Alzheimer's diagnosis, treatment and clinical research.

A copy of the transcript can be accessed here: http://www.actinogen.com.au/wp-content/uploads/2015/04/ACW_CC_140415_Transcript.pdf and a copy of the recording will be able to be accessed on the Actinogen website under the Resources section in the Knowledge Database tab later in the morning.

ENDS

Actinogen Medical

Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au**@BillKetelbey****About Actinogen Medical**

Actinogen Medical is an Australian biotechnology company focused on the treatment of Alzheimer's disease and prodromal Alzheimer's/Mild Cognitive Impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer's dementia. It is developing a novel drug to treat Alzheimer's disease and other age-related neurodegenerative diseases. The lead candidate Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques – hallmarks of Alzheimer's. The Company is currently undertaking a second Phase I multiple ascending dose trial in healthy volunteers with results expected in mid-2015. Actinogen Medical plans to initiate a Phase II study in Alzheimer's and Mild Cognitive Impairment in 2016.

About Xanamem™

Xanamem™ is under development as a potential new therapy for Alzheimer's disease and prodromal Alzheimers/Mild Cognitive Impairment, conditions with a multi- billion dollar market potential. Xanamem™'s novel mechanism of action sets it apart from existing Alzheimer's treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer's disease.